An Update on Overall Survival (Os) and Follow-On Therapies in Break-3, a Phase Iii, Randomized Trial: Dabrafenib (D) Vs. Dacarbazine (Dtic) in Patients (Pts) with Braf V600E Mutation-Positive Metastatic Melanoma (Mm)Axel Hauschild, Paul B. Chapman, J. Grobb et al.|Annals of Oncology|2014Cited by 37
P79.02 Updated OS and Time to Second Progression with First-Line Camrelizumab Plus Chemo vs Chemo for Advanced Non-Squamous NSCLCC. Zhou, Chengping Hu, Lizhu Lin et al.|Journal of Thoracic Oncology|2021Cited by 7